about
Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.Early dissemination seeds metastasis in breast cancer.The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.The Diagnosis and Treatment of Ectopic Pregnancy.Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer PatientsHospital versus individual surgeon's performance in laparoscopic hysterectomyThe presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.Laparoscopic Supracervical Hysterectomy and Laparoscopic Total Hysterectomy in Patients with Very Large Uteri: a Retrospective Single-Center Experience at a Major University Hospital.Second Opinion Expert Pathology in Endometrial Cancer: Potential Clinical Implications.Laparoscopic supracervical hysterectomy using EnSeal vs standard bipolar coagulation technique: randomized controlled trial.A prospective, randomized clinical comparison between UltraCision and the novel sealing and cutting device BiCision in patients with laparoscopic supracervical hysterectomy.Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry.Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.L1CAM: amending the "low-risk" category in endometrial carcinoma.Sentinel lymph node mapping using SPECT/CT and gamma probe in endometrial cancer: an analysis of parameters affecting detection rate.Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network.Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score.Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients.Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer.Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications.Prevalence and prognostic value of disseminated tumor cells in primary endometrial, cervical and vulvar cancer patients.Sexual Function, Contraception, Relationship, and Lifestyle in Female Medical Students.Interim analysis of a randomized controlled trial comparing laparoscopic radiofrequency volumetric thermal ablation of uterine fibroids with laparoscopic myomectomy.Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer.Are hormonal components of oral contraceptives associated with impaired female sexual function? A questionnaire-based online survey of medical students in Germany, Austria, and Switzerland.Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
P50
Q31107007-6916F8C9-E301-4212-A9F2-D9152C507410Q33562263-99103157-232C-48BD-A83B-FD04BC7EF27AQ35619770-93394B71-C2A6-47CA-B64D-6B6A2E63083EQ36275228-1AC5A7FC-EAE9-44AE-8BBB-BDC86FE4037CQ36482582-1D7D1749-52A8-43E6-85EE-7D60275AE96FQ37578344-2BAB8B5C-27DA-4455-B1D0-6C85CCECAF56Q37690073-BE1B5371-7E46-4E68-83AD-0008844B32B1Q37740249-4CFA61F3-5175-4424-87A7-1981FAA58D11Q38376940-299BB777-2BFD-4CD5-8EA2-6D6B6D052628Q38449540-021E8648-FFFD-45A7-A2E8-1A3F9BA3ABA0Q38451586-A2B82C47-B3C6-4816-A05D-C67BD24D93F7Q38606464-B586406E-552E-4AA6-88CD-AD7215347978Q38677937-4470F13E-C4DF-405B-B116-057981179A79Q38754407-ECFEDE3B-EB01-4505-B1D5-7EB15FEC0092Q38815450-68A29A5E-9EF9-4C5D-94AC-C42FEA0A6027Q38857145-89F5C390-C257-452F-8A69-2E7FD00FC0B6Q38884752-75D28EFB-9780-45D0-9E9A-D16257D152A6Q38903826-2481A426-B70F-46D7-B788-F0E86F30AC9AQ39002420-E6E83AC0-DE23-489A-B918-D4093D941048Q39022352-6A160E7D-FF17-4F68-A807-51D7E3D0A603Q39285061-8E0489B0-6DF2-4C80-9B42-1844B990771AQ39297043-AFE7C2C8-8CF5-4FC8-8AA0-1A1400EB2835Q39334149-4F4C80C5-B656-4D8C-A9DE-589151AACD0AQ39985714-AE400355-CB72-49E0-8404-63495A63D822Q40142509-556D103A-42AF-45E9-83BE-62C34DF7BCD8Q41024010-E57F9BFE-EFF1-40D6-882E-309EA266ED21Q41382683-58A4CE4B-D068-4377-B734-605651227420
P50
description
onderzoeker
@nl
name
Florin-Andrei Taran
@ast
Florin-Andrei Taran
@en
Florin-Andrei Taran
@es
Florin-Andrei Taran
@sl
type
label
Florin-Andrei Taran
@ast
Florin-Andrei Taran
@en
Florin-Andrei Taran
@es
Florin-Andrei Taran
@sl
altLabel
Florin Andrei Taran
@en
prefLabel
Florin-Andrei Taran
@ast
Florin-Andrei Taran
@en
Florin-Andrei Taran
@es
Florin-Andrei Taran
@sl